THOUSAND OAKS, Calif., May 16, 2023 /PRNewswire/ — Amgen AMGN today issued the following statement in response to the U.S. Federal Trade Commission’s (FTC) complaint seeking to block the company’s proposed acquisition of Horizon Therapeutics plc: “Amgen is disappointed by the FTC’s decision and remains committed to completing this acquisition,…Read More
AMGEN RESPONDS TO FTC ACTION RE PROPOSED ACQUISITION OF HORIZON THERAPEUTICS Amgen NASDAQAMGN
